suPAR can predict mild or severe outcome of COVID-19 infection – New study in Critical Care

2020-04-30

suPAR is an early predictor of severe respiratory failure in patients with COVID-19 pneumonia.

A new study published in Critical Care by Nikoletta Rovina, MD, PhD et al, may be of major importance in the management of COVID-19.

The study shows that suPAR (soluble urokinase plasminogen activator receptor) can act as an early predictor of the risk of severe respiratory failure in patients with COVID-19.

Läs hela meddelandet på ViroGates hemsida.

Läs mer..



Västra Hamnen Corporate Finance AB | Jungmansgatan 12 | 211 11 Malmö | 040-200 250 | info@vhcorp.se